Effect of BiLu treatment on GVHD in tumor-bearing mice
Effector cells . | BiLu treatment . | No. of mice with GVHD/total no. of mice . |
---|---|---|
C57BL/6 | - | 23/27 |
C57BL/6 | + | 5/25 |
BALB/c | - | 1/32 |
BALB | + | 0/20 |
BALB, 2 ×* | - | 7/27 |
BALB/c, 2 ×* | + | 0/10 |
Effector cells . | BiLu treatment . | No. of mice with GVHD/total no. of mice . |
---|---|---|
C57BL/6 | - | 23/27 |
C57BL/6 | + | 5/25 |
BALB/c | - | 1/32 |
BALB | + | 0/20 |
BALB, 2 ×* | - | 7/27 |
BALB/c, 2 ×* | + | 0/10 |
F1 mice were inoculated with B16-EpCAM melanoma cells (5 × 103) after conditioning with 4 Gy TBI. One day later, 30 × 106 splenocytes derived either from C57 or BALB mice were injected intraperitoneally.
Two injections of BALB splenocytes were done at intervals of 4 days